Actively Recruiting
Contrast Enhanced Spectral Mammography for the Evaluation of Pathologic Nipple Discharge
Led by M.D. Anderson Cancer Center · Updated on 2025-10-09
66
Participants Needed
1
Research Sites
315 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This clinical trial studies contrast enhanced spectral mammography (CESM) for the evaluation of pathologic nipple discharge. CESM is similar to standard mammography, but it includes an intravenous (by vein) injection of an iodine-based contrast, which makes tissue and blood vessels more visible in scans. The goal of this trial is to learn if CESM, is better than standard mammography in quickly and efficiently determining the cause of nipple discharge and detecting breast cancer, if present. CESM may increase the chance of finding breast cancers and lower the risk of having unnecessary biopsies.
CONDITIONS
Official Title
Contrast Enhanced Spectral Mammography for the Evaluation of Pathologic Nipple Discharge
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women presenting to MDACC for the evaluation of pathologic nipple discharge as the main or accompanying symptom
- Age between 25 and 85 years
- Willing to participate and undergo IV placement
- Able to receive iodinated contrast injection
- Able to provide informed consent
You will not qualify if you...
- History of allergic reaction to iodinated contrast
- History of anaphylactic reaction to any substance without prior uneventful iodine-based contrast administration
- Renal insufficiency
- Pregnancy or lactation within the last 6 months
- Breast surgery on the symptomatic breast within 6 months if located within 5 cm from the nipple
- Breast biopsy on the symptomatic breast within the last 2 months if located within 5 cm from the nipple
- Breast MRI within 24 months before presenting with symptoms (except MRI done contemporarily with CESM for new symptoms)
- Known breast cancer or active inflammatory breast condition (abscess or mastitis) in the breast of concern
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
M D Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
O
Olena Weaver, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here